←Back to Expert Scholars
Translational Medicine / 转化医学Squamous NSCLC Advances
Martin Reck
MD, PhD
🏢Lung Clinic Grosshansdorf🌐Germany
Head, Department of Thoracic Oncology
88
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Martin Reck led KEYNOTE-024 and multiple squamous NSCLC immunotherapy trials. His work helped establish pembrolizumab combinations as first-line standard for squamous disease. He continues leading European squamous lung cancer trial programs.
Share:
🧪Research Fields 研究领域
KEYNOTE trials
Immunotherapy
Squamous NSCLC
First-line therapy
Chemotherapy-IO
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Martin Reck 的研究动态
Follow Martin Reck's research updates
留下邮箱，当我们发布与 Martin Reck（Lung Clinic Grosshansdorf）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment